OPTIMIZATION OF INFERTILITY PRE-TREATMENT AND PROTOCOLS OF CONTROLLED OVULATION INDUCTION IN FEMALE PATIENTS WITH POLYCYSTIC OVARY SYNDROME IN IVF PROGRAMS
DOI:
https://doi.org/10.11603/2415-8798.2018.4.9815Keywords:
polycystic ovary syndrome, infertility, controlled ovulation induction, oocyte quality, FT-500 Plus, inositol, vitamin DAbstract
Infertility is one of the pressing issues of modern worldwide medicine, despite of the success achieved in reproductive medicine in recent decades. This issue has not only medical but also socio-economic importance, as it leads to a deterioration of the demographic situation in the country. The level of infertility in our country is 1–20 % of the total number of couples. It should be noted that 40 % of infertility pairs are seeking to solve the problem from 5 to 25 years, and 30–35 % require assisted reproductive technologies (ART). The causes of infertility growth are the deterioration of reproductive health of the population, an increase in the incidence of endometriosis, uterine fibroids, ovarian cysts, endocrine disorders, inflammatory diseases of the pelvic organs, widespread use of contraceptives, late first pregnancy, as well as an important role is played by the deterioration of the ecological and economic situation in the country. It should be noted that polycystic ovary syndrome (PCOS) greatly contributes to the problem of infertility. This polycystic syndrome disease is one of the most common endocrinological pathologies in women of reproductive age. According to the literature, PCOS is diagnosed in almost 50 % of women with disorders of menstrual and ovulatory functions, and more than in 40 % is the cause of anovulatory infertility.
The aim of the study – to increase the effectiveness of infertility treatment by using integration pre-treatment in patients with PCOS before controlled ovulation induction in IVF protocols.
Materials and Methods. 150 women were diagnosed with PCOS. Patients were divided into 2 groups. In the group 1 there were 72 women who took folic acid (400 micrograms) daily for 2–3 months before ovulation induction, and in the IVF protocol. The group 2 consisted of 78 patients with PCOS, who received combined therapy of vitamin complex FT 500-Plus and vitamin D3 supplement Aquadetrim. In both groups, superovulation induction with recombinant gonadotropin corifollitropin-alfa – ELONVA was performed. On the 5–7th day of the protocol, antagonist-GnRH (ant-GnRH) Orgalutran (0.25 mg/daily) was administered. On the 8th day since ELONVA was administrated, recombinant-FSH (r-FSH) Puregon was used until the maturation of the oocytes, and as a trigger agonist-GnRH (a-GnRH) Dyferelin was used. The size of the ovaries and the state of the follicular apparatus was evaluated by the ultrasound examination, as well as the presence of pathological lesions .
Results and Discussion. According to our own research, it was found out that in patients who used the preconception FT-500 Plus (inositol, folic acid, glutathione, lutein, zinc, vitamin C, vitamin E, selenium) and Vit.D3 pre-treatment and during all of the IVF protocol period there were significantly higher oocyte quality indices, a lower incidence of immature and degenerate cells and a higher percentage of blastocyst cleavage. The use of an agonist-GnRH as an ovulation trigger reduces the manifestations of OHSS.
Conclusions. The use of a combination of vitamin complexes in patients with PCOS helps to obtain oocytes of better quality, reduces the percentage of immature and degenerate eggs, increases the incidence of pregnancy. The use of the short protocol with the GnRH antagonist and the GnRH agonist trigger in this group of patients is more physiological and reduces the risk of complications.
References
Grodnitskaya, Ye.E., & Kurtser, M.A. (2015). Defitsit vitamina D u zhenshchin s sindromom polikistoznykh yaichnikov [Vitamin D deficiency in women with polycystic ovary syndrome]. Problemy reproduktsii – Problems reproduction, 21 (5), 38-42 [in Russian].
Gromova, O.A., Torshin, I.Yu., Limanova, O.A., Gromov, A.N., & Grishina, T.R. (2013). Sistematicheskiy analiz molekulyarno-fiziologicheskikh effektov mio-inozitola – dannyye molekulyarnoy biologii, eksperementalnoy i klinicheskoy meditsiny [Systematic analysis of the molecular and physiological effects of myo-inositol - the data of molecular biology, experimental and clinical medicine]. Effektivnaya farmakoterapiya v akusherstve i ginekologii – Effective pharmacotherapy in obstetrics and gynecology, 8, 37-43 [in Russian].
Kamenov, Z., Kolarov, G., Gatva, A., Karlomano, Dzh., & Dzhenatstsani, A.D. (2015). Induktsiya ovulyatsii mio-inozitolom, otdelno i v sochetanii s tsitratom klomifena pri sindrome polikistoznykh yaichnikov s insulino rezistentnostyu. Ginekologicheskaya yendokrinologiya – Gynecological endocrinology, 31, 2, 131–138 [in Russian].
Lesovska, S.H. (2017). Stan vprovadzhennia dopomizhnykh reproduktyvnykh tekhnolohii v Ukraini [The state of introduction of auxiliary reproductive technologies in Ukraine]. Slovo o zdorovye Vypusk – The word about healthy, 8, [in Russian].
Mozhinskaya, Yu.V., Belik, S.N., Podgornyy, I.V., & Yevdokimova, Ye.G. (2016). Vozmozhnosti ispolzovaniia vitamina D3 v lechenii besplodiya, obuslovlennogo sindromom polikistoznykh yaichnikov [Possibilities of using vitamin D3 in the treatment of infertility caused by polycystic ovary syndrome]. Molodoy uchenyy – Young Scientist, 18, 1, 58-60 [in Russian].
Nakaz Ministerstva okhorony zdorovia Ukrainy vid 09.09.2013 r. Pro zatverdzhennia Poriadku zastosuvannia dopomizhnykh reproduktyvnykh tekhnolohii v Ukraini – Order of the Ministry of Health of Ukraine dated 09.09.2013. On Approval of the Procedure for the Use of Assisted Reproductive Technologies in Ukraine.
Nakaz Ministerstva okhorony zdorovia Ukrainy vid 29.11.2013 r. № 1030/102 Pro udoskonalennia systemy planuvannia simi ta okhorony reproduktyvnoho zdorovia v Ukraini.
Podzolkova, N.M., & Koloda, Yu.A. (2016). Sovremennyye predstavleniya o sindrome polikistoznykh yaichnikov [Modern ideas about polycystic ovary syndrome]. Farmateka – Farmateka, 3, 8-15.
Tatarchuk, T.F., Bulavenko, O.V., Kapshuk, I.M., & Tarnopolska, V.O. (2015). Nedostatnist vitaminu D v henezi porushen reproduktyvnoho zdorovia [Vitamin D deficiency in the genesis of reproductive health disorders]. Ukrainskyi medychnyi chasopys – Ukrainian Medical Journal, 5 (109), 56-60 [in Ukrainian].
Shenkin, A. (2006). Micronutrients in health and disease. Postgrad Med J, 82, 559-567. doi: 10.1136/pgmj.2006.047670
Angioni, S. (2004). Correlation of ovarian stromal hypertrophy to hyperandrogenism and insulin resistance in young women with PCOS. Presented at the 11-th World Congress of Gynecological Endocrinology Florence, 1 (18), 163-164.
D’Anna, R., DiBenedetto, V., Rizzo, P., Raffone, E., Interdonato, M.L., Corrado, F., & Di Benedetto, A. (2012). Myo-inositolmaypreventgestationaldiabetesin PCOS women. Gynecol. Endocrinol, 28, 6, 440-442.
Gardner, D.K., Lane, M., Stevens, J., Schlenker, T., & Schoolcraft, W.B. (2000). Blastocysts core affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril, 6, 1155-1158.
Thomas, D.R. (2006). Vitamins in aging, health, and longevity. Clinical Interventions in Aging, 1 (1), 81-91.
Garg, D., & Tal, R. (2016). Inositol Treatmentand ART OutcomesinWomenwith PCOS. International Journal of Endocrinology, p. 9. Article ID1979654.
De Leo, V., La Marca, A., Cappelli, V., Stendardi, A., Focarelli, R., Musacchio, M.C., & Piomboni, P. (2012). Evaluation of the treatment with D-chiro-inositol on levels of oxidative stress in pcos patients. Minerva Ginecol, 64, 6, 531-538.
Lazzaroni-Tealdi1, E., Barad, D.H., Albertini1, D.F., Yu, Yao, Kushnir, V.A., Russell H., … & Gleicher, N. (2015). Oocyte Scoring Enhances Embryo-Scoringin Predicting Pregnancy Chanceswith IVF Where It Counts Most. Plos One, 2, 1-13. DOI:10.1371/journal.
Barthelmess, E.K., & Naz, R.K. (2015). Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). Author manuscript, p. 1-23.
Grant, W.B., Wimalawansa, S.J., Holick, M.F., Cannell, J.J., Pludowski, P., Lappe, J.M., … & May, P. (2015). Emphasizing the health benefits of vitamin D for those with neuro developmental disorders and intellectual disabilities. Nutrients, 7, 1538-1564.
Irani, M., & Merhi, Z. (2014). Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril, 102 (2), 460-468.
Ishchenko, A.I., Agadzhanyan, E.S., Ishchenko, A.A., Gorbenko, O.Yu. (2015). Sovremennyye podkhody v lechenii sindroma Shteyna-Leventalya [Modern approaches to the treatment of Stein-Levenal syndrome]. Arkhiv akusherstva i ginekologii im. V.F. Snegireva – V.F. Snegirev Archive of obstetrics and gynecology, 2 (4), 20-25 [in Russian].
Hilger, J., Friedel, A., Herr, R., Rausch, T., Roos, F., Wahl, D.A., … & Hoffmann, K. (2014). A systematic review of vitamin D status in populations worldwide. Br J Nutr, 14, 111 (1), 23-45.
Kim, J.J., Choi, Y.M., Chae, S.J., Hwang, K.R., Yoon, S.H., Kim, M.J., … & Kim, J.G. (2014). Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med., 41 (2), 80-85.
Lizneva, D., Walker, W., Brakta, S., Gavrilova-Jordan, L., Azzis, R., & Suturina, L. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril., 106 (6), 1510-1520.
Practice Committee of American Society for Reproductive Medicine (2012). Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertility and Sterility, 99 (1), 63-63. doi:10.1016/j.fertnstert. 2012.09.023.
Rotterdam ESHRE/ASRM-Sponsored Consensus Workshop Group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum. Reprod., 19 (1), 41-47.
Roupa, Z., Polikandrioti, M., & Sotiropoulou, P. (2009). Causes of infertility in women at reproductive age. Health Science Journal, 3, 2, 80-87.
Tehrani, H., Mostajeran, F., & Shahsavari, S. (2014). The effect of calcium and Vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with polycystic ovarian syndrome: A clinical trial study. J Res. Med. Sci., 19, 875-880.
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012). Effects of myoinositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol. Endocrinol, 28, 7, 509-515.
Youssef, M.A., Van der Veen, F., Al-Inany, H.G., Mochtar, M.H., Griesinger, G., Nagi Mohesen, M., … & van Wely, M. (2014). Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database of Systematic Reviews, 10, 1-73.
Downloads
Published
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
